| Date | Event | Description |
|---|---|---|
| 20 August 2020 | New citation required and conclusions have changed | Results and conclusion stratified per compound (alirocumab and evolocumab) and comparison (active treatment or placebo), finding higher certainty of evidence for placebo comparisons than against active treatment. After removing trials evaluating the terminated compound bococizumab (three) and RG7652 (one), 23 RCTs were included. |
| 20 August 2020 | New search has been performed | Evidence up to date to 2 December 2019. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.